Sana Biotechnology, Inc. 8-K

What Happened Sana Biotechnology, Inc. (SANA) filed an 8‑K on June 5, 2026 reporting results from its June 4, 2026 annual meeting. Stockholders elected three Class II directors—Hans E. Bishop, Robert Nelsen, and Alise S. Reicin, M.D.—each to a three‑year term expiring at the 2029 annual meeting. Stockholders also ratified the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Key Details

• Director election votes (For / Withheld / Broker non‑votes):
  • Hans E. Bishop: 117,452,573 / 57,148,432 / 30,606,441
  • Robert Nelsen: 160,384,193 / 14,216,812 / 30,606,441
  • Alise S. Reicin, M.D.: 149,865,546 / 24,735,459 / 30,606,441
• Auditor ratification vote: Ernst & Young LLP — For: 203,932,500; Against: 831,419; Abstain: 443,527.
• Filing: Form 8‑K filed June 5, 2026; meeting held June 4, 2026.

Why It Matters These outcomes confirm the board composition for the next three years and formally secure the company’s independent auditor for the 2026 fiscal year. For investors, director elections affect board oversight and strategic direction, while auditor ratification affects continuity of financial reporting and audit processes. The vote totals (including broker non‑votes) show varying levels of shareholder support for individual nominees.